ISPOR - PGI22 - COST-EFFECTIVENESS OF VEDOLIZUMAB VERSUS USTEKINUMAB IN UNITED KINGDOM CROHN'S DISEASE PATIENTS WHO PREVIOUSLY FAILED TNF INHIBITOR THERAPY

Full Text

PGI22 - COST-EFFECTIVENESS OF VEDOLIZUMAB VERSUS USTEKINUMAB IN UNITED KINGDOM CROHN'S DISEASE PATIENTS WHO PREVIOUSLY FAILED TNF INHIBITOR THERAPY

Abstract

Authors

M. Wilson A. Lucas

Back to Volume 21, Supplemental S3

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now